Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors

Experimental Hematology

Volumn 39, Issue 4, 2011, Pages 457-472.e3

  Batista, Ana ^a,b   Barata, João T ^c   Raderschall, Elke ^a   Sallan, Stephen E ^a   Carlesso, Nadia ^d   Nadler, Lee M ^a   Cardoso, Angelo A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; DOXORUBICIN; INITIATION FACTOR 4G; INTERLEUKIN 7; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN S6; RAPAMYCIN; TEMSIROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

MAMMALIA;

EID: 79952708745     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.01.005     Document Type: Article

References (60)

1. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N Engl J Med 2002, 347:1593-1603.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000, 60:3689-3695.
4. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
5. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
6. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
7. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998, 95:1432-1437.
8. Gingras A.C., Raught B., Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999, 68:913-963.
9. Ruvinsky I., Sharon N., Lerer T., et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005, 19:2199-2211.
10. Sekulic A., Hudson C.C., Homme J.L., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000, 60:3504-3513.
11. Vogt P.K. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 2001, 7:482-484.
12. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
13. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
14. Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin. Annu Rev Immunol 1996, 14:483-510.
15. Geoerger B., Kerr K., Tang C.B., et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001, 61:1527-1532.
16. Mondesire W.H., Jian W., Zhang H., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004, 10:7031-7042.
17. Yan H., Frost P., Shi Y., et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006, 66:2305-2313.
18. Wei G., Twomey D., Lamb J., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10:331-342.
19. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145.
20. Hagner P.R., Schneider A., Gartenhaus R.B. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010, 115:2127-2135.
21. Chapuis N., Tamburini J., Green A.S., et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010, 24:1686-1699.
22. Funk P.E., Stephan R.P., Witte P.L. Vascular cell adhesion molecule 1-positive reticular cells express interleukin-7 and stem cell factor in the bone marrow. Blood 1995, 86:2661-2671.
23. Sakata T., Iwagami S., Tsuruta Y., et al. Constitutive expression of interleukin-7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line. J Leukoc Biol 1990, 48:205-212.
24. Barata J.T., Cardoso A.A., Boussiotis V.A. Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?. Leuk Lymphoma 2005, 46:483-495.
25. Barata J.T., Silva A., Brandao J.G., Nadler L.M., Cardoso A.A., Boussiotis V.A. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004, 200:659-669.
26. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
27. Chan S.M., Weng A.P., Tibshirani R., Aster J.C., Utz P.J. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007, 110:278-286.
28. Cullion K., Draheim K.M., Hermance N., et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009, 113:6172-6181.
29. Barata J.T., Boussiotis V.A., Yunes J.A., et al. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood 2004, 103:1891-1900.
30. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
31. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
32. Irish J.M., Hovland R., Krutzik P.O., et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228.
33. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
34. Barata J.T., Cardoso A.A., Nadler L.M., Boussiotis V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001, 98:1524-1531.
35. Easton J.B., Houghton P.J. mTOR and cancer therapy. Oncogene 2006, 25:6436-6446.
36. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
37. Stiles B., Groszer M., Wang S., Jiao J., Wu H. PTENless means more. Dev Biol 2004, 273:175-184.
38. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
39. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98:10314-10319.
40. Silva A., Yunes J.A., Cardoso B.A., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008, 118:3762-3774.
41. Costa L.F., Balcells M., Edelman E.R., Nadler L.M., Cardoso A.A. Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood 2006, 107:285-292.
42. Veiga J.P., Costa L.F., Sallan S.E., Nadler L.M., Cardoso A.A. Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol 2006, 34:610-621.
43. Sipkins D.A., Wei X., Wu J.W., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005, 435:969-973.
44. Qiuping Z., Jei X., Youxin J., et al. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res 2004, 64:7579-7587.
45. Youn B.S., Kim Y.J., Mantel C., Yu K.Y., Broxmeyer H.E. Blocking of c-FLIP(L)-independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood 2001, 98:925-933.
46. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
47. Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004, 101:3130-3135.
48. McMahon L.P., Choi K.M., Lin T.A., Abraham R.T., Lawrence J.C. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7428-7438.
49. Avellino R., Romano S., Parasole R., et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005, 106:1400-1406.
50. Brown V.I., Fang J., Alcorn K., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 2003, 100:15113-15118.
51. Sharma D., Kumar S.S., Raghu R., Khanam S., Sainis K.B. Differential modulation of mitogen driven proliferation and homeostasis driven proliferation of T cells by rapamycin, Ly294002 and chlorophyllin. Mol Immunol 2007, 44:2831-2840.
52. Kawamata S., Sakaida H., Hori T., Maeda M., Uchiyama T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998, 91:561-569.
53. Liang J., Zubovitz J., Petrocelli T., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002, 8:1153-1160.
54. Giles F.J., Cortes J.E., Kantarjian H.M. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med 2005, 5:615-623.
55. Frost P., Moatamed F., Hoang B., et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004, 104:4181-4187.
56. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
57. Teachey D.T., Obzut D.A., Cooperman J., et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006, 107:1149-1155.
58. Raje N., Kumar S., Hideshima T., et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004, 104:4188-4193.
59. Xu Q., Thompson J.E., Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005, 106:4261-4268.
60. Chiarini F., Fala F., Tazzari P.L., et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009, 69:3520-3528.